Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
1 hedge funds and large institutions have $0 invested in Genocea Biosciences, Inc. in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less capital invested
Capital invested by funds: $1 → $0 (-$1)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MPCA
Madison Park Capital Advisors
Seattle,
Washington
|
-$1 |
GNCA Hedge Fund Activity: Q4 2024 in Review
1 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q4 2024, worth a combined $0 — down 100% from $1 a quarter earlier.
Fund positioning in GNCA was balanced in Q4 2024: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Madison Park Capital Advisors, exiting entirely with an estimated $1 sold.
- 1 institutional investor held Genocea Biosciences, Inc. (GNCA) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $0 of Genocea Biosciences, Inc. stock for Q4 2024, down 100% quarter-over-quarter.
- 1 fund opened new Genocea Biosciences, Inc. positions in Q4 2024 and 1 closed out, a net change of 0 holders.
- The largest Genocea Biosciences, Inc. seller in Q4 2024 was Madison Park Capital Advisors, an estimated $1 sold.
Based on aggregated 13F filings for Q4 2024.